HemaCare Reports Profitable Third Quarter
Sales Growth and Lower Costs Drive Operating Results
LOS ANGELES, CA -- 11/10/2008 -- HemaCare Corporation (OTCBB: HEMA)
announced today third quarter 2008 results. Sales from continuing
operations for the quarter were $9.5 million, 12 percent greater than
comparable operations in the same period of 2007. Blood Products revenue
increased 19 percent to $7.6 million, while Blood Services revenue declined
8 percent to $1.9 million.
Income from operations was $59,000 for the quarter compared to a loss of
$404,000 for the same quarter of 2007. Net income was $285,000, which
included $396,000, principally one-time other income from legal
settlements, and a $170,000 loss from discontinued operations. For the
same quarter of 2007, the Company reported a loss of $5,596,000, which
included a $4,569,000 loss from discontinued operations. General and
administrative expenses declined 9 percent, or $148,000, from third quarter
2007 levels.
For the first nine months of 2008, the Company generated $27.7 million in
revenue from continuing operations, representing a $2.4 million, or 10
percent, increase from comparable operations in the same period of 2007.
The Company's income from operations generated $422,000 in the first nine
months, compared to a $1,337,000 loss for the same period of 2007,
representing a nearly $1.8 million improvement year over year. Net income
for the first nine months of 2008 was $800,000, including $92,000 income
from discontinued operations, whereas for the same period of 2007, the
Company generated a net loss of $6.4 million, including $4.4 million loss
from discontinued operations.
Commenting on the results, John Doumitt, the Company's Chief Executive
Officer, stated, "HemaCare is making good progress with profitable
operations for the past four quarters. We continue to manage costs and
maintain profitability while still investing in actions that will either
grow sales or improve efficiency. We have successfully come through the
summer months, which are a seasonal challenge for the entire blood industry
and look forward to continued progress in building shareholder value."
About HemaCare Corporation
Founded in 1978, HemaCare is a provider of blood products and services to
the healthcare industry. HemaCare is licensed by the FDA and accredited by
the AABB. The Company focuses on the customized delivery of human
blood-related products and services.
This press release contains "forward-looking statements" under the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995
(Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended). Statements herein that
are not historical facts are forward-looking statements pursuant to the
safe harbor provisions referenced above. You may also identify
forward-looking statements by use of the words "anticipates," "expects,"
"intends," "plans" and similar expressions. These forward-looking
statements include, but are not limited to, statements regarding the
progress in returning HemaCare to growth and profitability and the
management team's continued identification of initiatives that will benefit
future results. Forward-looking statements are inherently subject to risks
and uncertainties some of which cannot be predicted or quantified. Such
risks and uncertainties include, without limitation, the following: the
Company reported losses for all of 2007 and may not return to
profitability; costs increasing more rapidly than market prices could
reduce profitability, changes in demand for blood products could affect
profitability, declining blood donations could affect profitability,
competition may cause a loss of customer and an inability to pass on
increases in costs thereby impacting profitability, operations depend on
services of qualified professionals and competition for their services is
strong, industry regulations and standards could increase operating costs
or result in closure of operations, the discontinuation of the operation of
the Company's Florida-based research subsidiary may hinder the Company's
ability to generate profits, the decrease in reimbursement rates may affect
profitability, not-for-profit status gives advantages to competitors, the
potential inability of the Company to meet future capital needs could
impact ability to operate; reliance on relatively few vendors for
significant supplies and services could affect the Company's ability to
operate; limited access to insurance could affect ability to defend against
possible claims; future technology for blood collection and blood
replacement; potential adverse effect from changes in the healthcare
industry, including consolidations, could affect access to customers; the
ability to attract, retain and motivate management and other skilled
employees; product safety and product liability could provide exposure to
claims and litigation; targeted partner blood drives involve higher
collection costs; environmental risks could cause the Company to incur
substantial costs to maintain compliance; the threat of business
interruption due to terrorism and the security measures taken in response
to terrorism could adversely impact profitability; business interruption
due to earthquakes could adversely impact profitability; the evaluation and
consideration of strategic alternatives, and other significant projects,
may distract management from reacting appropriately to business challenges
and lead to reduced profitability; the Articles of Incorporation and
Rights Plan could delay or prevent an acquisition or sale of the Company;
quarterly revenue and operating results may fluctuate in future periods,
and the Company may fail to meet investor expectations; the Company's stock
is traded on the OTC Bulletin Board and therefore is subject to greater
market risk than those of exchange-traded stocks since they are less
liquid; the Company's stock price could be volatile; future sales of equity
securities could dilute the Company's common stock; the lack of dividend
payments could impact the price of the Company's common stock; the
evaluation of internal control and remediation of potential problems will
be costly and time consuming and could expose weaknesses in financial
reporting; and the other risks and uncertainties discussed from time to
time in the documents HemaCare files with the Securities and Exchange
Commission. Although the Company believes that the expectations reflected
in such forward-looking statements are reasonable, it can give no assurance
that such expectations will prove to be correct. Consequently, future
events and actual results could differ materially from those set forth in,
contemplated by, or underlined in the forward-looking statements contained
herein. The Company undertakes no obligation to update any of these
forward-looking statements to reflect actual results or events or
circumstances after the date hereof.
(Financial Table Follows)
HemaCare Corporation
Condensed Consolidated Data
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2008 2007 2008 2007
------------ ------------ ------------- -----------
Statements of
Income
(Operations):
Revenues $ 9,474,000 $ 8,433,000 $ 27,642,000 $ 25,205,000
Gross Profit $ 1,511,000 $ 1,196,000 $ 4,797,000 $ 3,473,000
------------ ------------ ------------- -----------
General and
administrative
expenses $ 1,452,000 $ 1,600,000 $ 4,375,000 $ 4,810,000(1)
Other income $ 396,000 $ - $ 331,000 $ -
------------ ------------ ------------- -----------
Income (loss)
before income
taxes and
discontinued
operations $ 455,000 $ (404,000) $ 753,000 $ (1,337,000)
Provision for
income taxes $ - $ 623,000 $ 45,000 $ 623,000
------------ ------------ ------------- -----------
Net income (loss)
from continuing
operations $ 455,000 $ (1,027,000) $ 708,000 $ (1,960,000)
------------ ------------ ------------- -----------
(Loss) income
from
discontinued
operations, net
of tax impact $ (170,000) $ (4,569,000) $ 92,000 $ (4,396,000)
------------ ------------ ------------- -----------
Net income
(loss) $ 285,000 $ (5,596,000) $ 800,000 $ (6,356,000)
============ ============ ============= ===========
Basic earnings
(loss) per
share $ 0.03 $ (0.64) $ 0.08 $ (0.74)
============ ============ ============= ===========
Diluted earnings
(loss) per
share $ 0.03 $ (0.64) $ 0.08 $ (0.74)
============ ============ ============= ===========
Weighted average
shares
outstanding
- basic 9,696,000 8,794,000 9,415,000 8,588,000
============ ============ ============= ===========
Weighted average
Shares
outstanding
- diluted 9,942,000 8,794,000 9,588,000 8,588,000
============ ============ ============= ===========
(1) Includes $326,000 in non-recurring severance expenses to the
Company's former Chief Executive Officer.
September 30, December 31,
2008 2007
------------ ------------
Balance Sheets:
Assets
Cash and cash equivalents $ 59,000 $ 420,000
Other current assets 8,609,000 7,135,000
Non-current assets 4,628,000 4,939,000
------------ ------------
Total assets $ 13,296,000 $ 12,494,000
============ ============
Liabilities and Shareholders' Equity
Current liabilities $ 8,308,000 $ 8,791,000
Long-term liabilities 668,000 631,000
Shareholders' equity 4,320,000 3,072,000
------------ ------------
Total liabilities and shareholders' equity $ 13,296,000 $ 12,494,000
============ ============